Josh Courtney McMullan

All Wales Ovarian Cancer Prehabilitation Project (AWOCPP)

Over 50% of patients with ovarian cancer are diagnosed with advanced disease (stage 3+) in Wales when treatment typically involves chemotherapy, combined with cytoreductive surgery. Postoperative morbidity is common resulting in prolonged hospital stays and delays in returning to chemotherapy. Patients with advanced ovarian cancer commonly have modifiable risk factors that can be targeted for improvement with personalised prehabilitation. Multimodal personalised prehabilitation has been shown to have a positive impact on perioperative outcomes and length of stay (LOS). Quality improvement methods were used to implement a multimodal prehabilitation programme for all patients with advanced ovarian cancer planned for surgery in Wales. A unique approach to determining an individual patient’s modifiable risk factors was devised that enabled a personalised prehabilitation programme to be created including exercise, smoking cessation, medical and nutritional optimisation and emotional support. Data were collected to enable future health economic evaluation of the programme in anticipation of national role out as standard of care. To evaluate if the prehabilitation intervention was impacting the quality of care, the following outcome measures were assessed: LOS, postoperative complications and surgery to chemotherapy interval (SCI). These measures were compared with a historical Welsh data set from 2018 to 2019 when access to prehabilitation was not available. Following the implementation of prehabilitation for ovarian cancer, the median LOS reduced from 6 to 5 days (p=0.29). There was a reduction in postoperative complications: from 16.9% to 12.7% (Grade 2), 4.4% to 1.8% (Grade 3), 0.6% to 0% (Grade 4+5). The median SCI following prehabilitation was 43.5 days (range 27–91) compared with 40 days (range 15–182 (p=0.65)). Prehabilitation has had a positive impact on the treatment pathways for advanced ovarian cancer in Wales. Means of improving patient engagement and establishing cost-effective delivery need to be developed to make this intervention standard of care.

Northern Ireland ovarian cancer prehabilitation project

Patients with ovarian cancer are often diagnosed late, in advanced stages (stages III–IV) and are often deconditioned due to disease burden. Frailty is reported in up to 60% of gynaecological oncology patients and many report malnutrition, anxiety and depression. As surgery is the mainstay of treatment for ovarian cancer, with maximum surgical effort being a priority, patients are at increased risk of perioperative morbidity and mortality. Multimodal prehabilitation aims to improve the functional capacity of surgical patients. Prehabilitation commonly includes physical, nutritional, medical optimisation, smoking cessation and emotional well-being interventions. Many surgical specialties have well established evidence for the use of prehabilitation showing a reduction in length of stay and perioperative complications. There is, however, limited evidence for the use of prehabilitation in the surgically vulnerable group of patients with advanced ovarian cancer. This project aimed to introduce a multimodal prehabilitation pathway for patients with advanced ovarian cancer. All patients with advanced ovarian cancer were included, regardless of the treatment modality decided at the regional gynaecological oncology multidisciplinary team meeting. The pathway included exercise, nutritional and psychological interventions. The outcome measures included the Rockwood Frailty Score, 6 min Walk Test (6MWT), 30 s Chair to Stand test, grip strength and Eastern Cooperative Oncology Group performance status as a measure of functional capacity. Nutritional intervention outcomes included the Malnutrition Universal Screening Tool (MUST) score, Body mass index and mid-arm circumference. The psychological intervention outcomes included a holistic needs assessment, the distress thermometer and EQ-5D-5L quality of life status. Of the 75 patients enrolled, 45 (60%) completed the project. In patients who completed the project improved 6MWT and 30-CST was observed in 67% and 44%, respectively, while 67% of patients with moderate to extreme anxiety/depression scores reported lowering from baseline level and 71% of patients with medium to high-risk MUST scores baseline weight was maintained or increased.

The malignant transformation of endometriosis: Is there a left lateral predisposition of ovarian clear cell and endometrioid carcinomas?

Endometriosis affects 10% of women of reproductive age. There is evidence for a left lateral predisposition of endometriotic lesions and a 1.9-fold greater risk of ovarian cancer in endometriosis. The aim of this study is to determine whether a left lateral predisposition of ovarian clear-cell carcinoma (CCC) and endometrioid carcinoma (EC) exists. A retrospective cohort study of all EC and CCC patients in Northern Ireland between March-2011 and June-2018. ANOVA was used to analyse preoperative prediction of stage, chi-squared (χ2) was used to compare left- and right-sided masses. Survival was estimated using Kaplan-Meier and log-rank test. A p-value <0.05 was considered significant. 158 patients were identified (95 EC, 55 CCC, 8 mixed). Mean age was 57.65 years with 69% presenting at stage 1. The mean CA125 was 559 U/mL (p = 0.850) and mean abdominal mass size was 14.12 cm (p = 0.732). The most common presenting symptom was an abdominal mass (37%). Despite 67% of patients having endometriosis on final pathology, only 8.9% had a known history pre-operatively. 51% of tumours were located on the left (p = 0.036). For unilateral tumours this was significant for EC (P = 0.002) but not for CCC (P = 0.555). The 1-, 3- and 5-year overall survival for all types/stages was 85%, 78% and 71% respectively. While CCC and EC are associated with endometriosis, only EC exhibits a left lateral predisposition. There is no association between preoperative CA125 or abdominal mass size and stage of disease.